arrow_back Back to App

Lowering Medicare Part D Prescription Drug Copays for Low-Income Individuals.

This bill aims to significantly reduce out-of-pocket costs for prescription drugs for low-income individuals enrolled in Medicare Part D. Starting in 2026, copayments for generic drugs will be eliminated entirely, while copayments for other drugs will be capped and adjusted annually based on inflation. This change provides substantial financial relief for seniors and disabled individuals needing essential medications.
Key points
Starting in 2026: Copayments for generic drugs under Medicare Part D for low-income individuals will be reduced to zero ($0).
Copayments for non-generic drugs will be adjusted annually based on the consumer price index (inflation), preventing large cost spikes.
Before 2026: Maximum copayments are set at $1 for generic/preferred multiple source drugs and $3 for all other drugs.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_S_3951
Sponsor: Sen. Casey, Robert P., Jr. [D-PA]
Process start date: 2024-03-14
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Cutting Copays Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_S_3951.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2024-03-14.

What are the main provisions?

Key points include:

  • Starting in 2026: Copayments for generic drugs under Medicare Part D for low-income individuals will be reduced to zero ($0).
  • Copayments for non-generic drugs will be adjusted annually based on the consumer price index (inflation), preventing large cost spikes.
  • Before 2026: Maximum copayments are set at $1 for generic/preferred multiple source drugs and $3 for all other drugs.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Casey, Robert P., Jr. [D-PA].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-26.

CATEGORIES

Health Benefits